Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ray-Coquard, Isabelle, Italiano, Antoine, Bompas, Emmanuelle, Le Cesne, Axel, Robin, Yves-Marie, Chevreau, Christine, Bay, Jacques-Olivier, Bousquet, Guilhem, Piperno-Neumann, Sophie, Isambert, Nicolas, Lemaitre, Laurent, Fournier, Charles, Gauthier, Eric, Collard, Olivier, Cupissol, Didier, Clisant, Stéphanie, Blay, Jean-Yves, Penel, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Sarcomas
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/
https://ncbi.nlm.nih.gov/pubmed/22285963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados